IRIS
GENOVA, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.571
NA - Nord America 2.879
AS - Asia 2.612
Continente sconosciuto - Info sul continente non disponibili 534
SA - Sud America 251
AF - Africa 49
OC - Oceania 6
Totale 18.902
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 12.145
US - Stati Uniti d'America 2.673
SG - Singapore 857
CN - Cina 626
BD - Bangladesh 467
VN - Vietnam 362
BR - Brasile 151
FR - Francia 150
HK - Hong Kong 100
CA - Canada 87
FI - Finlandia 60
DE - Germania 49
AR - Argentina 40
IN - India 35
GB - Regno Unito 33
JP - Giappone 31
NL - Olanda 31
JM - Giamaica 24
ID - Indonesia 22
MX - Messico 18
ZA - Sudafrica 17
MY - Malesia 16
CR - Costa Rica 15
HN - Honduras 15
EC - Ecuador 14
CO - Colombia 13
RU - Federazione Russa 13
GT - Guatemala 12
CH - Svizzera 11
PH - Filippine 11
TR - Turchia 11
UA - Ucraina 11
PY - Paraguay 10
UZ - Uzbekistan 10
IQ - Iraq 9
VE - Venezuela 9
ES - Italia 8
IE - Irlanda 8
PL - Polonia 8
SA - Arabia Saudita 7
SV - El Salvador 7
DZ - Algeria 6
GR - Grecia 6
NP - Nepal 6
RO - Romania 6
UY - Uruguay 6
AU - Australia 5
LB - Libano 5
PR - Porto Rico 5
RS - Serbia 5
TT - Trinidad e Tobago 5
KE - Kenya 4
NI - Nicaragua 4
PK - Pakistan 4
SE - Svezia 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
BB - Barbados 3
CL - Cile 3
EG - Egitto 3
ET - Etiopia 3
HR - Croazia 3
KW - Kuwait 3
MA - Marocco 3
OM - Oman 3
PE - Perù 3
SC - Seychelles 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BE - Belgio 2
BS - Bahamas 2
GA - Gabon 2
GE - Georgia 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
SI - Slovenia 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
AL - Albania 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GD - Grenada 1
GP - Guadalupe 1
GY - Guiana 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
LC - Santa Lucia 1
Totale 18.352
Salva come PNG Salva come JPEG
Città #
Genoa 5.244
Genova 3.882
Vado Ligure 1.284
Rapallo 1.273
San Jose 493
Singapore 397
Ashburn 388
Council Bluffs 148
Lauterbourg 136
Ho Chi Minh City 107
New York 98
Hong Kong 95
Beijing 92
Hanoi 83
St Louis 82
Santa Clara 57
Chicago 55
Helsinki 54
Los Angeles 53
Milan 53
Rome 42
Frankfurt am Main 40
Phoenix 38
Buffalo 34
Boardman 27
Bordighera 26
Tokyo 26
Dallas 23
Houston 23
Naples 23
Philadelphia 18
Toronto 18
Atlanta 16
Amsterdam 15
Orem 15
São Paulo 15
Tianjin 15
Brasília 14
Da Nang 14
Montreal 14
Haiphong 12
Biên Hòa 11
Guatemala City 11
City of London 10
Jamaica Plain 10
Kingston 10
Mexico City 10
New Delhi 10
Newark 10
San José 10
Washington 10
Bologna 9
Charlotte 9
Guangzhou 9
Las Vegas 9
Turin 9
Catania 8
Dublin 8
Jacksonville 8
Johannesburg 8
Queens 8
Brooklyn 7
Fort Lauderdale 7
Hải Dương 7
Kuala Lumpur 7
Miami 7
Piscataway 7
Richmond 7
Rio de Janeiro 7
Seattle 7
Tashkent 7
Warsaw 7
Billings 6
Cagliari 6
Columbus 6
Denver 6
Jakarta 6
Kansas City 6
Lappeenranta 6
North Charleston 6
Padua 6
Palermo 6
Phủ Lý 6
Pittsburgh 6
Princeton 6
San Salvador 6
Shenzhen 6
Asunción 5
Bari 5
Can Tho 5
Chennai 5
Detroit 5
Guayaquil 5
Jersey City 5
London 5
Memphis 5
Nashville 5
Orlando 5
San Pedro Sula 5
Shanghai 5
Totale 14.961
Salva come PNG Salva come JPEG
Nome #
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. 294
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 218
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 207
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 190
CORRELATION BETWEEN B7-H4 EXPRESSION AND SURVIVAL OF NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH NIVOLUMAB 189
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors 183
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 182
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 182
Harnessing NK Cells for Cancer Treatment 181
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 180
Belagenpumatucel-L for the treatment of non-small cell lung cancer 180
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients 177
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 176
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 176
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 175
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 170
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 170
Radiomic detection of EGFR mutations in NSCLC 168
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 163
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab 160
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells 159
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 159
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 156
Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports 155
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 153
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 153
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 152
Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer 152
Oral vinorelbine in the treatment of non-small-cell lung cancer. 151
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives 151
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 150
Afatinib for the treatment of advanced non-small-cell lung cancer. 150
Expression of ribonucleotide reductase subunit-2 and thymidylate synthase correlates with poor prognosis in patients with resected stages I-III non-small cell lung cancer 147
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer 147
Liquid biopsy in non-small cell lung cancer: Highlights and challenges 147
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors 147
Novel emerging molecular targets in non-small cell lung cancer 147
Next-generation sequencing workflow for NSCLC critical samples using a targeted sequencing approach by ion torrent PGM™ platform 144
Immune Checkpoint Inhibitors-Related Myastenia Gravis, Myocarditis and Myositis: A Systematic Review of Cases 142
Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors 142
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. 142
Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients 141
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 141
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 141
Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study 140
Afatinib for the treatment of non-small cell lung cancer 140
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 140
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade 139
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 138
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 138
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients 138
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 138
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 137
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update 137
A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry 136
An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis 135
Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management 132
Potential application of cryobiopsy for histo-molecular characterization of mediastinal lymph nodes in patients with thoracic malignancies: a case presentation series and implications for future developments 132
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms 131
Approaches to Fertility Preservation for Young Women With Breast Cancer 131
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors 130
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives 128
Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancer 128
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 128
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 125
CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells 125
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 124
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 123
Primary endobronchial melanoma: a case report and clinical management indications 120
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 120
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 119
Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics 119
Role of microRNAs in malignant mesothelioma. 118
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 116
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 113
Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer 113
Palliative treatment of life-threatening hemoptysis with silicone stent insertion in advanced lung cancer 113
ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium 111
Antibody–drug conjugates for lung cancer in the era of personalized oncology 111
Radiomic-based diagnostics in oncology: challenges toward clinical practice 111
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 111
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 110
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 110
Pemetrexed for the treatment of non-small cell lung cancer. 109
Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers 109
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review 109
Rapid On-Site Evaluation Performed by an Interventional Pulmonologist: A Single-Center Experience 108
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 108
Hematopoietic growth factors in lung cancer 106
Vinflunine for the treatment of non-small cell lung cancer 105
Call for ensuring cancer care continuity during COVID-19 pandemic 104
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Focus on challenging populations 103
Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples 102
Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression 102
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer 101
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma 100
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines 99
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 98
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 98
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 98
Totale 13.957
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.919
article - articoli 73.478
book - libri 0
conference - conferenze 495
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 499
Totale 149.391
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.067 0 0 31 76 63 86 30 253 140 120 75 193
2022/20231.509 136 104 26 141 262 242 17 138 227 27 172 17
2023/20241.016 39 107 34 137 76 151 80 58 46 71 44 173
2024/20253.429 115 198 93 274 431 353 312 602 155 217 309 370
2025/20267.563 743 307 563 645 807 503 958 341 644 756 636 660
2026/20271.215 684 262 269 0 0 0 0 0 0 0 0 0
Totale 18.902